Evidence map›Paper›PMID 15547092›Full record

ArticleAnnals of the rheumatic diseases2004

Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.

V Bjerkeli, B Halvorsen, J K Damås, I Nordøy, A Yndestad, P Aukrust, S S Frøland

Open access · bronzeAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Xenobiotic exposure and autoimmune hepatitis.Hepatitis research and treatment · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

V BjerkeliResearch Institute for Internal Medicine, Medical Department, Rikshospitalet University Hospital, N-0027 Oslo, Norway. vigdis.bjerkeli@klinmed.uio.no.
B Halvorsen
J K Damås
I Nordøy
A Yndestad
P Aukrust
S S Frøland
Oslo University Hospital · NOMed-Storm Innovation (Norway) · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnhanced activity of matrix metalloproteinases (MMPs) has been reported to have a pathogenic role in several diseases such as cancer and cardiovascular disorders, and seems also to play a part in certain autoimmune diseases.

objectiveTo examine whether enhanced MMP activity may also have a role in the pathogenesis of Wegener's granulomatosis (WG).

methodsIn a study group of 15 patients with WG and 15 controls, plasma levels and gene expression were measured in freshly isolated peripheral blood mononuclear cells (PBMCs) of several MMPs and their endogenous inhibitors (that is, tissue inhibitors of metalloproteinases (TIMPs)) by enzyme immunoassays and RNase protection assay, respectively.

resultsWhereas patients with WG in remission had enhanced gene expression of several MMPs and TIMPs in PBMCs, those with active disease had a selective up regulation of MMP-2 and MMP-8 compared with healthy controls, and a down regulation of TIMP-1 and TIMP-3 compared with other patients with WG. Moreover, plasma levels of TIMP-1 and MMP-8 correlated significantly with C reactive protein levels, further supporting an association between activation of the MMP/TIMP system and disease activity in WG. Finally, these changes in MMP/TIMP expression in WG were accompanied by increased total MMP activity in PBMC supernatants, particularly in those with active disease, suggesting a matrix degrading net effect.

conclusionThese findings suggest that disturbed MMP and TIMP activity has a role in the pathogenesis of WG.

Indexed as

AdultAgedAged, 80 and overCells, CulturedC-Reactive ProteinFemaleGene Expression RegulationGranulomatosis with PolyangiitisHumansMaleMatrix Metalloproteinase 8Matrix MetalloproteinasesMiddle AgedRNA, MessengerTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of MetalloproteinasesC-Reactive ProteinMatrix Metalloproteinase 8Matrix MetalloproteinasesRNA, MessengerTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinases

Identifiers

PMID15547092
PMCPMC1754858
OpenAlexW2117216467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.